Global AIDS, TB, Malaria fund implements damage limitation as donations fall short
This article was originally published in Scrip
The Global Fund to Fight AIDS, Tuberculosis and Malaria has had to cancel its next funding round and implement new measures for the use of its now insufficient resources. The organisation had targeted $20 billion for its Round 11 funding, with a bottom threshold of $13 billion, but in the event it has garnered only $11.7 billion. Budget challenges in donor countries and low interest rates contribute to a continuing negative outlook.
You may also be interested in...
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.